Related Experiment Video
Updated: Sep 3, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.1K
Biotinylated Polymer-Ruthenium Conjugates: In Vitro and In Vivo Studies in a Triple-Negative Breast Cancer Model.
Leonor Côrte-Real1, Ana Rita Brás1,2,3, Adhan Pilon1
1Centro de Química Estrutural, Institute of Molecular Sciences and Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016 Lisboa, Portugal.
Pharmaceutics
|July 27, 2022
Summary
Researchers developed novel ruthenium(II) organometallic complexes for triple-negative breast cancer therapy. Compound 1 demonstrated potent anti-cancer effects, inducing apoptosis and controlling tumor growth, offering a promising new therapeutic avenue.
Area of Science:
- Organometallic Chemistry
- Cancer Therapeutics
- Nanomedicine
Background:
- Triple-negative breast cancer (TNBC) lacks effective targeted therapies, necessitating novel treatment strategies.
- Current chemotherapeutics like cisplatin have limitations and significant side effects.
- Targeted drug delivery systems can enhance efficacy and reduce systemic toxicity.
Purpose of the Study:
- To synthesize and evaluate a new family of ruthenium(II) organometallic complexes for TNBC treatment.
- To investigate a multi-targeting approach combining active (biotin) and passive (polylactide) targeting for enhanced cancer cell uptake.
- To assess the in vitro and preliminary in vivo efficacy and safety of the most promising compound.
Main Methods:
- Synthesis of ruthenium(II) complexes with general formula [Ru(η⁵-CpR)(P)(2,2'-bipy-4,4'-PLA-biotin)][CF₃SO₃].
- In vitro cytotoxicity assays against MDA-MB-231 TNBC cells, comparing with cisplatin.
- Cell uptake mechanism studies using biotin competition assays.
- Evaluation of effects on cancer hallmarks (apoptosis, proliferation, cytoskeleton) and preliminary in vivo studies in mice.
Main Results:
- Synthesized ruthenium(II) complexes exhibited potent IC₅₀ values (2.3-14.6 µM) against TNBC cells, outperforming cisplatin.
- Compound 1 showed the best biological activity, with uptake primarily mediated by SMVT receptors via biotin.
- Compound 1 induced apoptosis, inhibited colony formation, disrupted the cytoskeleton, and showed a trend in controlling tumor growth in vivo with acceptable safety at tested doses.
Conclusions:
- The novel biotin- and PLA-conjugated ruthenium(II) complex (Compound 1) demonstrates significant promise as a targeted therapeutic agent for triple-negative breast cancer.
- The multi-targeting strategy effectively enhances cellular uptake and anti-cancer activity.
- Compound 1 represents a potential new avenue for TNBC therapy, warranting further investigation.
